FORMULATION AND IN VITRO EVALUATION OF DEFERASIROX ORO-DISPERSIBLE TABLETS

Abstract

Oral drug delivery remains the preferred route for administration of various drugs. Recent developments in technology, led
to the development of oro-dispersible tablets (ODT’s) with improved patient compliance and convenience. Deferasirox an
oral iron chelator is used in patients suffering from chronic iron over load and treatment of patients with anemia. Deferasirox is a poorly soluble drug so; ODT’s is prepared to increase the release rate. The present work is carried out by using super disintegrants such as crospovidine, croscarmellose sodium and sodium starch glycolate (SSG). All these formulations are compressed by direct compression technique. The developed tablets are evaluated for hardness, weight variation, friability, dispersion time, disintegration time and in -vitro dissolution studies. The tablet is compared with an innovator (ASUNRA 400mg, NOVARTIS) and is concluded that dispersible tablets of Deferasirox (400mg) with the superdisintegrant crospovidone (total weight of tablet-900 mg) showed rapid release rate and enhance dissolution. The developed Deferasirox ODT’s has better patient compliance and effective therapy.